Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Assets Average (2016 - 2025)

Lineage Cell Therapeutics' Assets Average history spans 15 years, with the latest figure at $101.1 million for Q4 2025.

  • For Q4 2025, Assets Average fell 3.62% year-over-year to $101.1 million; the TTM value through Dec 2025 reached $101.1 million, down 3.62%, while the annual FY2025 figure was $112.9 million, 5.4% up from the prior year.
  • Assets Average reached $101.1 million in Q4 2025 per LCTX's latest filing, up from $90.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $159.5 million in Q1 2022 to a low of $90.2 million in Q3 2025.
  • Average Assets Average over 5 years is $118.0 million, with a median of $112.5 million recorded in 2023.
  • Peak YoY movement for Assets Average: soared 44.88% in 2021, then dropped 25.76% in 2023.
  • A 5-year view of Assets Average shows it stood at $152.9 million in 2021, then decreased by 16.66% to $127.4 million in 2022, then decreased by 18.7% to $103.6 million in 2023, then grew by 1.27% to $104.9 million in 2024, then dropped by 3.62% to $101.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Assets Average are $101.1 million (Q4 2025), $90.2 million (Q3 2025), and $101.3 million (Q2 2025).